NEW YORK (GenomeWeb News) – Akrivis Technologies today said that it has inked an agreement with United States Biological to co-develop, manufacture, and sell research products based on Akrivis' Z-Tect technology.
The Z-Tect technology is a nanotechnology-based technique for detecting unusually low levels of protein and molecular targets. According to the firms, the technology has "ultra-low limits of detection several thousand fold lower than currently achievable," and will make it possible to "vastly improve the early detection of cancer biomarkers in vitro."
"As we progress towards developing ultrasensitive clinical diagnostics, this agreement provides Akrivis with US Biological's extensive US and international sales and distribution channels for the broad and imminent commercialization of its Z-Tect ultrasensitive detection platform for research use," Joel Berniac, CEO of Cambridge, Mass.-based Akrivis Technologies, said in a statement. "In addition, Akrivis and US Biological will co-develop new ultrasensitive kits based on US Biological's extensive catalog of biomolecular targets, biomarkers and antibodies, covering the oncology, CNS, cardiovascular, inflammation, and auto-immune therapeutic areas."
Salem, Mass.-based US Biological is a provider of antibodies, molecular biology products, and biochemicals used in research laboratories and production facilities.
Financial and further terms of the alliance were not disclosed.